143 related articles for article (PubMed ID: 15602725)
1. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
Adekale MA; Cane PA; McCrae MA
J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
[TBL] [Abstract][Full Text] [Related]
2. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
3. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
4. Resistance to protease inhibitors.
Kuritzkes DR
J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
[TBL] [Abstract][Full Text] [Related]
5. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
Malet I; Wirden M; Derache A; Simon A; Katlama C; Calvez V; Marcelin AG
AIDS; 2007 Apr; 21(7):871-3. PubMed ID: 17415044
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
7. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
8. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
[TBL] [Abstract][Full Text] [Related]
10. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
11. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
[No Abstract] [Full Text] [Related]
12. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
[TBL] [Abstract][Full Text] [Related]
14. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
15. In vivo genetic variability of the HIV-1 vif gene.
Wieland U; Hartmann J; Suhr H; Salzberger B; Eggers HJ; Kühn JE
Virology; 1994 Aug; 203(1):43-51. PubMed ID: 8030283
[TBL] [Abstract][Full Text] [Related]
16. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
[TBL] [Abstract][Full Text] [Related]
17. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
[TBL] [Abstract][Full Text] [Related]
19. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
20. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]